AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28372549
Drug: Iron sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron sucrose (1.0 g over 10 doses)
Trial: 12181401
Drug: Imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib mesylate 400 mg daily
Trial: 12181401
Drug: Imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib mesylate 600 mg daily
Trial: 8031206
Drug: Lovastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (20 mg/d, increased to 40 mg/d and 80 mg/d based on response)
Trial: 8031206
Drug: Niacin (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niacin (1.5 g/d, increased to 3 g/d and 4.5 g/d based on response)
Trial: 31091372
Drug: Dabigatran (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran (150 mg or 110 mg twice daily)
Trial: 29175902
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg oral aspirin daily for up to 24 weeks
Trial: 23492458
Drug: Right-side stellate
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Right-side stellate ganglion block (SGB) using 8 mL 0.75% ropivacaine for 4 times
Trial: 16855454
Drug: Modafinil during
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Modafinil during open-label treatment
Trial: 16855454
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of Modafinil during double-blind treatment phase
Trial: 10837282
Drug: 5.1 g
RxNorm normalized name: POVIDONE-IODINE 5.1 g in 1 L TOPICAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.1 g psyllium twice daily
Trial: 31005929
Drug: Gut microbiome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gut microbiome transfer (28 capsules of frozen microbial suspension)
Trial: 31005929
Drug: Placebo (28
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (28 capsules of saline)
Trial: 22992309
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (Laser, Sham laser, Needle)
Trial: 20384520
Drug: CD34(+) cell
RxNorm normalized name: Autologous CD34+ cells encoding βA-T87Q-Globin gene
DrugBank: Betibeglogene autotemcel (DB16900)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD34(+) cell therapy
Trial: 16273791
Drug: TNF blocker
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TNF blocker therapy
Trial: 8738880
Drug: Oxytocin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin (0.5 IU, intravenous infusion within 2.5 min via a forearm catheter)
Trial: 2009998
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 1 mg/kg
Trial: 2009998
Drug: MTX (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX (1 mg/kg) systemic injection on days 3, 5, and 7 after local injection
Trial: 2009998
Drug: Sulprostone (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulprostone (500 micrograms) systemic injection on the 1st 2 postlocal injection days
Trial: 27109624
Drug: Naltrexone (NTX;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (NTX; 25 mg OD for 2 days, then 50 mg OD for 3 days)
Trial: 19212971
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment for low panic-high worry and high panic-high worry sub-groups
Trial: 19212971
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment for low panic-low worry subjects
Trial: 19212971
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment for high worry subjects
Trial: 31923099
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (dietary protein intake of 0.9 g/kg/day)
Trial: 29449290
Drug: ReTrain intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ReTrain intervention (including an introductory one-to-one session, ten twice-weekly group classes, a closing one-to-one session, and three drop-in sessions over 3 months)
Trial: 24346625
Drug: Further acupuncture
RxNorm normalized name: HOMOSALATE 10 g in 100 mL / OCTOCRYLENE 7 g in 100 mL / OCTISALATE 5 g in 100 mL / AVOBENZONE 3 g in 100 mL TOPICAL LOTION [CO-BB-54431 Featuring You Hydrating Skin Enhancing Tint SPF30-270 FURTHER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Further acupuncture treatment during the follow-up period
Trial: 24346625
Drug: Not wanting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not wanting to use medications
Trial: 24346625
Drug: Using additional
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using additional therapies
Trial: 385025
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (6 mg piretanide, 9 mg piretanide, 1 mg bumetanide)
Trial: 23827100
Drug: Prednisolone (PSL,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (PSL, 1.5 mg/kg for 2-4 weeks and subsequently stepwise reduction)
Trial: 23827100
Drug: Dexamethasone (HDD,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (HDD, 40 mg/day, d1-4)
Trial: 23827100
Drug: Rituximab plus
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab plus HDD (rituximab 100 mg on days 7, 14, 21, 28 and HDD)
Trial: 15691867
Drug: l-NAME (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-NAME (180 µg.kg(‐1).h(‐1))
Trial: 12162933
Drug: Inhibitors of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhibitors of cholesterol absorption, acyl coenzyme A‐cholesterol acyltransferase, microsomal triglyceride transfer protein, cholesteryl ester transfer protein, liver X receptor agonists
Trial: 7726492
Drug: Clarithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin (500 mg every 12 h for five doses)
Trial: 7726492
Drug: Erythromycin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (250 mg every 6 h for nine doses)
Trial: 17100739
Drug: Vehicle with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle with 308-nm monochromatic excimer light (MEL) therapy
Trial: 12385678
Drug: AMX/CA 2000/125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMX/CA 2000/125 mg bid
Trial: 10385761
Drug: Alteplase (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alteplase (intravenous infusion of a total dose of 100 mg over a 2‐hour period, including an initial 10‐mg bolus)
Trial: 2174446
Drug: Doxycycline 100
RxNorm normalized name: doxycycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg per day for 3 weeks
Trial: 26105170
Drug: Raltegravir 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir 800 mg twice daily initially then 400 mg twice daily after 4 weeks (arm 2)
Trial: 24315882
Drug: Ramosetron (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramosetron (5 μg oral, once daily for 12 weeks)
Trial: 9846858
Drug: Sucrose polyester
RxNorm normalized name: polyester-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose polyester (60 mL)
Trial: 8081594
Drug: Actiferrin Compositum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actiferrin Compositum (1 capsule per day from 36th week, increasing to 2 capsules per day until childbirth)
Trial: 20306535
Drug: Garlic capsules
RxNorm normalized name: Garlic 500 MG Oral Capsule, Liquid Filled [GARLIC CAPSULES]
DrugBank: Garlic (DB10532)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic capsules (656 mg daily)
Trial: 30582271
Drug: Valsartan/Amlodipine 80/5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan/Amlodipine 80/5 mg
Trial: 16154016
Drug: Amlodipine 5-10
RxNorm normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5-10 mg adding perindopril 4-8 mg as required
Trial: 1416875
Drug: Isepamicin (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isepamicin (7.5 mg/kg) with piperacillin (4 g every 12 h for four doses)
Trial: 26414912
Drug: one tablet
RxNorm normalized name: Hydone Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet weekly (one/week)
Trial: 26414912
Drug: one tablet
RxNorm normalized name: Hydone Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet twice weekly (two/week)
Trial: 26414912
Drug: Steady-state daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steady-state daily dosing serum TFV and PBMC TFV-DP
Trial: 20940646
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (manual massage and compression)
Trial: 12651168
Drug: Compression treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compression treatment
Trial: 11109969
Drug: Starting dose
RxNorm normalized name: Austedo 6 MG Starting Dose Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose of recombinant follicle stimulating hormone (FSH) followed by highly purified urinary FSH
Trial: 17924872
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g of cinnamon (OGTT(cin))
Trial: 17924872
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g of cinnamon taken 12 h before (OGTT(cin12hpre))
Trial: 9537699
Drug: Calcium-restricted diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-restricted diet (500 mg/day, oxalate-rich products discouraged, normalization of animal protein and sodium)
Trial: 681526
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment strategy
Trial: 30422156
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus bevacizumab (arm A)
Trial: 30422156
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus cetuximab (arm B)
Trial: 29051274
Drug: Immediate-release oral
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release oral morphine
Trial: 16514812
Drug: Captopril administration
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril administration
Trial: 3061717
Drug: Frusemide injection
RxNorm normalized name: furosemide Injection
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Frusemide injection and standing
Trial: 24010577
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg cobimetinib oral dose (tablets)
Trial: 24010577
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg rabeprazole daily for 5 days prior to cobimetinib administration
Trial: 2179550
Drug: Cyclosporine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (5 mg/kg)
Trial: 7191300
Drug: triamterene preparation
RxNorm normalized name: Triamterene
DrugBank: Triamterene (DB00384)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: triamterene preparation 3
Trial: 26010890
Drug: Full behavioural
RxNorm normalized name: Full Marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full behavioural activation treatment (ten sessions)
Trial: 19052779
Drug: Outpatient cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient cognitive behavioural treatment (CBT)
Trial: 16449106
Drug: Foley with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foley with extra-amniotic saline infusion
Trial: 15267006
Drug: Volume expansion
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume expansion with 300 ml saline during CM administration
Trial: 15267006
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of at least 2,000 ml saline within 12 h before and after CM application
Trial: 11687322
Drug: Course in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Course in psychosocial oncology for nurses, consisting of four 3-hour weekly lessons and follow-up discussions at termination and 5 months later.
Trial: 9224082
Drug: Aciclovir suspension
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aciclovir suspension 15 mg/kg five times a day for seven days
Trial: 26947328
Drug: Metformin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (250 mg daily)
Trial: 20589368
Drug: Weekly bisphosphonates
RxNorm normalized name: methylene diphosphonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly bisphosphonates
Trial: 20589368
Drug: Annual zoledronic
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Annual zoledronic acid infusions
Trial: 19430310
Drug: Torasemide (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torasemide (8 mg/d)
Trial: 19430310
Drug: Azosemide (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azosemide (60 mg/d)
Trial: 9322191
Drug: Milk fat
RxNorm normalized name: MILK FAT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk fat (40 g of fat/m2 body surface area)
Trial: 27693004
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (general)
Trial: 10331109
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg daily) with pindolol (7.5 to 10 mg daily)
Trial: 28419068
Drug: TX‐004HR 4,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TX‐004HR 4, 10, and 25 μg
Trial: 25384338
Drug: nonhormonal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nonhormonal therapy
Trial: 23642343
Drug: Heparins (unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparins (unfractionated heparin, heparinoids, or low-molecular-weight heparin)
Trial: 10523401
Drug: Aspirin or
RxNorm normalized name: aspirin Oral Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin or placebo
Trial: 11323369
Drug: Tramadol 1
RxNorm normalized name: tramadol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 1 mg/kg with ondansetron 0.1 mg/kg
Trial: 28785879
Drug: Doravirine 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doravirine 1200 mg
Trial: 12610241
Drug: Willingness to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Willingness to pay for depression treatment at baseline
Trial: 12610241
Drug: Willingness to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Willingness to pay for depression treatment at six-month follow-up
Trial: 10638900
Drug: Dextrose infusion
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose infusion (4 mg x kg(‐1) x min(‐1))
Trial: 8866920
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg didanosine as a single agent
Trial: 8866920
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg trimethoprim + 1000 mg sulphamethoxazole
Trial: 8866920
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg trimethoprim + 1000 mg sulphamethoxazole + 200 mg didanosine
Trial: 6504632
Drug: Intramuscular vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular vitamin E administration (100 mg/kg/d for at least 8 weeks, first dose within 8 hours of life)
Trial: 24623104
Drug: GC1113 intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GC1113 intravenous 0.3-5 μg/kg
Trial: 24623104
Drug: GC1113 subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GC1113 subcutaneous 1-8 μg/kg
Trial: 15735445
Drug: Single intrapartum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intrapartum nevirapine (NVP) dose
Trial: 9660028
Drug: Control (V)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (V) - 1 U containing 10(5.4) 50% tissue culture infectious dose of vaccinia virus, administered once a week for 13 weeks and then once every 2 weeks for a total of 12 months.
Trial: 25795408
Drug: Linsitinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linsitinib (150 mg oral, twice daily)
Trial: 24060561
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (4 tablets of 100 mg imatinib)
Trial: 24060561
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (1 tablet of 400 mg imatinib)
Trial: 18986387
Drug: Bortezomib (1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib (1.3 mg/m², days 1, 4, 8, and 11 for eight 3-week cycles, then days 1, 8, 15, and 22 for three 5-week cycles)
Trial: 18986387
Drug: Dexamethasone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (40 mg/d, days 1-4, 9-12, and 17-20 for four 5-week cycles, then days 1-4 only for five 4-week cycles)
Trial: 14668456
Drug: Four-drug regimen
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-drug regimen
Trial: 7829945
Drug: Prednisolone tablets
RxNorm normalized name: Prednisolone Tablets
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone tablets (1 mg/kg body wt/day up to 70 mg) for six successive days, then gradually reduced over the next four days
Trial: 3341273
Drug: Adriamycin (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adriamycin (90 mg/m2 given over 2 days, once a month for 5 months)
Trial: 17542353
Drug: Cipramil 40
RxNorm normalized name: Cipramil 40 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cipramil 40 mg
Trial: 17366918
Drug: Fructose infusion
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fructose infusion
Trial: 18591524
Drug: Vapocoolant spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vapocoolant spray
Trial: 28282703
Drug: Water spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water spray (placebo)
Trial: 21618201
Drug: Subcutaneous abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous abatacept (125 mg SC on days 1 and 8, then weekly; plus IV loading dose ∼10 mg/kg on day 1)
Trial: 21618201
Drug: Intravenous abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous abatacept (∼10 mg/kg on days 1, 15, and 29, then every 4 weeks)
Trial: 31039807
Drug: Intravenous abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous abatacept
Trial: 16961169
Drug: Gabapentin preparation
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin preparation 1 (400 mg)
Trial: 16961169
Drug: Gabapentin preparation
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin preparation 2 (400 mg)
Trial: 30035581
Drug: Assessment-only treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessment-only treatment as usual (TAU)
Trial: 23855131
Drug: Non-sodium restricted
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-sodium restricted diet with diuretics (sodium chloride 6500-8000 mg daily)
Trial: 23855131
Drug: Sodium restricted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium restricted diet with diuretics (sodium chloride 5000 mg daily)
Trial: 18563956
Drug: Intramuscular aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intramuscular aripiprazole 5 mg
Trial: 18563956
Drug: Oral aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral aripiprazole 5 mg
Trial: 8735776
Drug: Iron solution
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iron solution with ascorbic acid added to domestic drinking water for 4 months
Trial: 1750592
Drug: Midazolam 15
RxNorm normalized name: midazolam 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 15 mg night sedation
Trial: 1750592
Drug: Flunitrazepam 2
RxNorm normalized name: flunitrazepam 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam 2 mg night sedation
Trial: 1750592
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam 5 mg